Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 19/20 | 0.57 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | FER | P16591 | 1/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14928750 | 1.00 | SYK (0.57) | SYKEML4ALKFERMAPK3 | |
| SCHEMBL14909399 | 1.00 | SYK (0.57) | SYKEML4ALKFERMAPK3 | |
| SCHEMBL14928778 | 0.99 | SYK (0.59) | SYKEML4ALKFERKCNH2 | |
| SCHEMBL14909418 | 0.99 | SYK (0.59) | SYKEML4ALKFERKCNH2 | |
| SCHEMBL14909414 | 0.99 | SYK (0.59) | SYKEML4ALKFERKCNH2 | |
| SCHEMBL14923652 | 0.99 | SYK (0.59) | SYKEML4ALKFERKCNH2 | |
| SCHEMBL14908988 | 0.94 | SYK (0.65) | SYKEML4ALKKCNH2 | |
| SCHEMBL14908991 | 0.94 | SYK (0.65) | SYKEML4ALKKCNH2 | |
| SCHEMBL14929192 | 0.94 | SYK (0.65) | SYKEML4ALKKCNH2 | |
| SCHEMBL14923629 | 0.93 | SYK (0.54) | SYKEML4ALKFERMAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | SYK 1/4885EML4 4794/4885ALK 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.